Real-World Experience with Pembrolizumab Treatment in Patients with Heavily Treated Recurrent Gynecologic Malignancies.

CONCLUSION: In real-world practice, pembrolizumab was feasible and effective in heavily treated recurrent gynecologic cancer patients with poor performance status who may not be eligible for enrollment in clinical trials.
PMID: 32975058 [PubMed - in process]

Source: Yonsei Medical Journal - September 27, 2020 Category: Universities & Medical Training Authors: Choi MC, Moon YW, Jung SG, Park H, Joo WD, Song SH, Lee C, Kim G, Kim KA Tags: Yonsei Med J Source Type: research